Lionco(603669)2024-11-04 08:43Financial Performance - Revenue for the first three quarters of 2024 reached 2.31 billion yuan, a year-on-year increase of 53.34% [1] - Net profit attributable to the parent company was -46.89 million yuan, with a reduction in loss of 51.45% [1] - Third-quarter revenue was 89.55 million yuan, a year-on-year increase of 137.26% [1] - Main pharmaceutical business grew by 48.42% year-on-year in the first three quarters [2] Strategic Initiatives - Participating in the 10th national centralized procurement for two products: Injection of Latamoxef Sodium and Injection of Esmolol Hydrochloride [2] - Entering the CMO business for the first time to maximize production capacity utilization [2] - Leveraging provincial alliance centralized procurement for core product Injection of Cefuroxime Sodium, covering 11 and 21 provinces respectively [2] - Implementing cost control measures through refined management [2] Product Portfolio - Injection of Latamoxef Sodium has a market capacity of approximately 3 billion yuan annually, with 9 qualified enterprises [2] - Injection of Huperzine A is a proprietary product with significant market potential, currently covering less than one-fifth of China [3][4] - Injection of Esmolol Hydrochloride has a market capacity of about 1.1 billion yuan, with 18 qualified enterprises [4] International Expansion - Partnering with French company Laboratoire Bailly-Creat for African and Southeast Asian markets [4] - Targeting Africa's pharmaceutical market with a population of 1.4 billion and annual drug consumption of over 10 billion USD [5] - Expanding to "Belt and Road" countries, with China having signed over 200 cooperation documents with 152 countries [5] R&D and Innovation - Obtained four new consistency evaluation approvals in 2024 [6] - Currently has 27 approved or deemed approved specifications and 8 R&D projects [6] - Transitioning from generic drugs to innovative drugs, with two new 2.2 class solid preparations initiated in 2024 [6] - R&D investment consistently exceeds 10% of revenue [7] Future Plans - Considering equity incentives and employee stock ownership plans [7] - Focusing on mergers and acquisitions to enhance product portfolio and scale [8] - Targeting innovative drugs, biological drugs, and companies with technical or policy barriers [8]